SynthesisFrontiers in oncology2025
The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment, and while overall survival (OS) and progression-free survival (PFS) are well-established, a comprehensive meta-analysis focusing on complete response (CR) and pathological complete response (pCR) with tislelizumab-based therapies in NSCLC is lacking. Methods: This systematic review and meta-analysis was conducted following PRISMA guidelines. A thorough literature search was performed across PubMed, Embase, and Web of Science. We included both randomized controlled trials and observational studies of tislelizumab in NSCLC, focusing on extracting data for radiological complete response (CR, based on RECIST 1.1 criteria) and pathological complete response (pCR, defined as absence of residual invasive cancer in resected surgical specimens). Risk of bias was assessed using the Cochrane Collaboration's tool and the Newcastle-Ottawa Scale. Statistical analyses were performed using the 'meta' package in R. 95% confidence intervals (CIs) and odds ratios (ORs) were calculated for CR and pCR, and subgroup analyses were conducted. Results: 7 studies were enrolled in the meta-analysis. The results on pCR showed significant heterogeneity (I Conclusion: Tislelizumab combined with chemotherapy significantly improves CR rates in NSCLC compared to chemotherapy alone. While pCR data exhibit high heterogeneity, the findings highlight tislelizumab's role in achieving deep tumor responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.